Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

All appraisals

1,189 appraisals, newest first, page 3 of 12
AppraisalMedicine pageNICE recommendationPublishedStatus
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B
NICE TA989
—Optimised (Innovative Medicines Fund)24 Jul 2024Current
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis
NICE TA988
Ivacaftor, TezacaftorRecommended24 Jul 2024Current
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)
NICE TA987
Lisocabtagene maraleucelTerminated (no company submission)10 Jul 2024Current
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over
NICE TA986
LebrikizumabOptimised10 Jul 2024Current
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma
NICE TA985
—Optimised3 Jul 2024Withdrawn
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy
NICE TA984
—Recommended19 Jun 2024Current
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
NICE TA983
PembrolizumabNot recommended12 Jun 2024Current
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)
NICE TA982
BaricitinibTerminated (no company submission)13 Jun 2024Current
Voxelotor for treating haemolytic anaemia caused by sickle cell disease
NICE TA981
—Optimised12 Jun 2024Current
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)
NICE TA980
NivolumabTerminated (no company submission)5 Jun 2024Current
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
NICE TA979
IvosidenibRecommended5 Jun 2024Current
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)
NICE TA978
ZanubrutinibTerminated (no company submission)29 May 2024Current
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over
NICE TA977
DabrafenibRecommended29 May 2024Current
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
NICE TA976
Trastuzumab deruxtecanTerminated (no company submission)29 May 2024Current
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under
NICE TA975
TisagenlecleucelRecommended15 May 2024Current
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma
NICE TA974
SelinexorOptimised15 May 2024Current
Atogepant for preventing migraine
NICE TA973
AtogepantOptimised15 May 2024Current
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)
NICE TA972
SirolimusTerminated (no company submission)22 May 2024Current
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
NICE TA971
RemdesivirOptimised Not recommended8 May 2024Current
Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments
NICE TA970
SelinexorRecommended8 May 2024Current
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)
NICE TA969
—Terminated (no company submission)30 Apr 2024Current
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE TA968
—Terminated (no company submission)25 Apr 2024Current
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over
NICE TA967
PembrolizumabOptimised1 May 2024Current
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)
NICE TA966
PembrolizumabTerminated (no company submission)24 Apr 2024Current
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)
NICE TA965
—Terminated (no company submission)28 Mar 2024Current
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma
NICE TA964
CabozantinibOptimised10 Apr 2024Current
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
NICE TA963
DostarlimabRecommended (Cancer Drugs Fund)3 Apr 2024Replaced by TA1064
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA962
OlaparibRecommended28 Mar 2024Current
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)
NICE TA961
—Terminated (no company submission)28 Mar 2024Current
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)
NICE TA960
SatralizumabTerminated (no company submission)27 Mar 2024Current
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
NICE TA959
DaratumumabOptimised27 Mar 2024Current
Ritlecitinib for treating severe alopecia areata in people 12 years and over
NICE TA958
RitlecitinibRecommended27 Mar 2024Current
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms
NICE TA957
MomelotinibOptimised20 Mar 2024Current
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over
NICE TA956
EtrasimodRecommended11 Mar 2024Current
Dupilumab for treating moderate to severe prurigo nodularis
NICE TA955
DupilumabNot recommended13 Mar 2024Current
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
NICE TA954
EpcoritamabOptimised6 Mar 2024Current
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema
NICE TA953
—Recommended13 Mar 2024Current
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
NICE TA952
TalazoparibRecommended21 Feb 2024Current
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer
NICE TA951
OlaparibRecommended7 Feb 2024Current
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over
NICE TA950
Nivolumab, RelatlimabOptimised7 Feb 2024Current
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over
NICE TA949
BelumosudilRecommended7 Feb 2024Current
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
NICE TA948
IvosidenibRecommended31 Jan 2024Current
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
NICE TA947
Loncastuximab TesirineOptimised31 Jan 2024Current
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
NICE TA946
OlaparibRecommended17 Jan 2024Current
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)
NICE TA945
TreosulfanTerminated (no company submission)30 Jan 2024Current
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer
NICE TA944
DurvalumabRecommended10 Jan 2024Current
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes
NICE TA943
—Optimised19 Dec 2023Current
Empagliflozin for treating chronic kidney disease
NICE TA942
—Optimised20 Dec 2023Current
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)
NICE TA941
RavulizumabTerminated (no company submission)20 Dec 2023Current
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)
NICE TA940
RavulizumabTerminated (no company submission)20 Dec 2023Current
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
NICE TA939
PembrolizumabOptimised13 Dec 2023Current
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)
NICE TA938
DupilumabTerminated (no company submission)7 Dec 2023Current
Targeted-release budesonide for treating primary IgA nephropathy
NICE TA937
BudesonideOptimised20 Dec 2023
Updated 9 Oct 2025
Replaced by TA1128
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)
NICE TA936
Idecabtagene vicleucelTerminated (no company submission)30 Nov 2023Current
Secukinumab for treating moderate to severe hidradenitis suppurativa
NICE TA935
SecukinumabOptimised6 Dec 2023Current
Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
NICE TA934
—Optimised29 Nov 2023Current
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)
NICE TA933
TisagenlecleucelTerminated (no company submission)29 Nov 2023Current
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)
NICE TA932
DecitabineTerminated (no company submission)23 Nov 2023Current
Zanubrutinib for treating chronic lymphocytic leukaemia
NICE TA931
ZanubrutinibOptimised22 Nov 2023Current
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments
NICE TA930
—Not recommended15 Nov 2023Current
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
NICE TA929
—Recommended1 Nov 2023Current
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine
NICE TA928
CabozantinibNot recommended1 Nov 2023Current
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
NICE TA927
GlofitamabRecommended17 Oct 2023Current
Baricitinib for treating severe alopecia areata
NICE TA926
BaricitinibNot recommended25 Oct 2023Current
Mirikizumab for treating moderately to severely active ulcerative colitis
NICE TA925
MirikizumabOptimised25 Oct 2023Current
Tirzepatide for treating type 2 diabetes
NICE TA924
TirzepatideOptimised25 Oct 2023
Updated 1 Sep 2025
Current
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)
NICE TA923
TabelecleucelTerminated (no company submission)19 Oct 2023Current
Daridorexant for treating long-term insomnia
NICE TA922
DaridorexantOptimised18 Oct 2023Current
Ruxolitinib for treating polycythaemia vera
NICE TA921
RuxolitinibRecommended18 Oct 2023Current
Tofacitinib for treating active ankylosing spondylitis
NICE TA920
TofacitinibOptimised18 Oct 2023Current
Rimegepant for treating migraine
NICE TA919
RimegepantOptimised18 Oct 2023Current
Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis
NICE TA918
BimekizumabOptimised11 Oct 2023Current
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
NICE TA917
DaratumumabRecommended25 Oct 2023Current
Bimekizumab for treating active psoriatic arthritis
NICE TA916
BimekizumabOptimised4 Oct 2023Current
Pegunigalsidase alfa for treating Fabry disease
NICE TA915
Pegunigalsidase-alfaRecommended4 Oct 2023Current
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
NICE TA914
PembrolizumabOptimised20 Sep 2023Current
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy
NICE TA913
MavacamtenOptimised6 Sep 2023Current
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
NICE TA912
Cipaglucosidase alfaRecommended15 Aug 2023Current
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
NICE TA911
SelpercatinibOptimised (Cancer Drugs Fund)26 Jul 2023Current
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)
NICE TA910
SemaglutideTerminated (no company submission)13 Jul 2023Current
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer
NICE TA909
LorlatinibNot recommended12 Jul 2023Replaced by TA1103
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
NICE TA908
OlaparibOptimised5 Jul 2023Current
Deucravacitinib for treating moderate to severe plaque psoriasis
NICE TA907
DeucravacitinibOptimised28 Jun 2023Current
Rimegepant for preventing migraine
NICE TA906
RimegepantOptimised5 Jul 2023Current
Upadacitinib for previously treated moderately to severely active Crohn’s disease
NICE TA905
UpadacitinibOptimised21 Jun 2023Current
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
NICE TA904
PembrolizumabRecommended21 Jun 2023Current
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer
NICE TA903
DarolutamideRecommended21 Jun 2023Current
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
NICE TA902
DapagliflozinRecommended21 Jun 2023Current
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)
NICE TA901
CemiplimabTerminated (no company submission)20 Jun 2023Current
Tixagevimab plus cilgavimab for preventing COVID-19
NICE TA900
—Not recommended14 Jun 2023Current
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)
NICE TA899
EsketamineTerminated (no company submission)6 Jun 2023Current
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
NICE TA898
DabrafenibOptimised14 Jun 2023Current
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
NICE TA897
DaratumumabOptimised6 Jun 2023Current
Bulevirtide for treating chronic hepatitis D
NICE TA896
BulevirtideOptimised7 Jun 2023Current
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
NICE TA895
Axicabtagene CiloleucelRecommended (Cancer Drugs Fund)7 Jun 2023Current
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma
NICE TA894
Axicabtagene CiloleucelNot recommended7 Jun 2023Current
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
NICE TA893
—Recommended (Cancer Drugs Fund)7 Jun 2023Current
Mosunetuzumab for treating relapsed or refractory follicular lymphoma
NICE TA892
MosunetuzumabNot recommended31 May 2023Current
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia
NICE TA891
IbrutinibRecommended31 May 2023Current
Difelikefalin for treating pruritus in people having haemodialysis
NICE TA890
—Recommended17 May 2023Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.